期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 108, 期 1, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2023.116122
关键词
Antibody level; BNT162b2; Booster dose; CoronaVac; COVID-19 vaccines; T-cell response
This study evaluated the antibody and T cell responses of homologous and heterologous booster doses for SARS-CoV-2 vaccines. The results showed that individuals who received heterologous boosters had higher antibody levels and higher levels of IFN-gamma, IL-2, and IL-13.
This study aimed to evaluate the antibody and T cell responses of homologous and heterologous booster doses for SARS-CoV-2 vaccines. Our study was performed on those with two doses of mRNA vaccine BNT162b2 (2B, n:44), those with heterologous booster dose BNT162b2 vaccine after two doses of inactivated vaccine CoronaVac (2S+1B, n:44), those with homologous booster dose vaccine CoronaVac after two doses of vaccine CoronaVac (3S, n:44) SARS-CoV-2 IgG antibody levels were significantly higher in individuals who received heterologous boosters(p<0.001). IFN-gamma, IL-2 and IL-13 median values were detected higher in 2S+1B group than in 3S group, respectively (p=0.112, p=0.057, p=0.341). Although the antibody levels in 2S+1B group were similar (p=0.153) to the 2B group; IFN-gamma, IL-2 and IL-13 levels were higher (p<0.001). In conclusion, supplementing an improved strategy based on inactivated vaccines with an mRNA vaccine as a heterologous booster is likely to be more beneficial in the course of the pandemic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据